HOME >> MEDICINE >> NEWS
Investigational drug brings new hope to kidney cancer patients

Preliminary results from a phase II trial of an investigational drug known as BAY 43-9006 demonstrate a significant short-term benefit for patients with advanced renal cell cancer, researchers from the University of Chicago and four other centers reported at the American Association of Cancer Research meeting in Boston, November 20.

Only 10 to 15 percent of patients with metastatic kidney cancer respond to standard immunotherapy, and there are no standard effective therapies for patients who fail or can't tolerate standard immunotherapy. In this study, however, 42 percent (21 of 50) of patients had their tumors shrink at least 25 percent within the first 12 weeks. Six of those patients had a reduction of 50 percent or more.

Another 26 percent (13 patients) had their tumors stabilize within 25 percent of pre-treatment size. The remaining 32 percent left the study because of progressive disease or adverse effects, such as a painful rash or diarrhea.

"This is the most exciting thing in oncology since Gleevec," said the study's lead investigator, Mark Ratain, M.D., professor of medicine and chief of clinical pharmacology at the University of Chicago. "All but one of the kidney cancer patients in this study had advanced disease that did not respond to at least one previous systemic treatment, yet almost half of them had a rapid and very encouraging response to this drug."

The study also served to validate a new approach to phase II trial design. Most phase II trials test the effects of a new drug on patients with a specific disease, such as colon cancer, and limit the goal to determining the percentage of patients who have at least a 50% reduction in tumor size. This study, a "randomized discontinuation trial," enrolled patients with many different tumor types for 12 weeks, then randomized patients with stable disease to placebo vs. continued treatment.

"This approach allows us to test a new drug for effects in many tumor
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
20-Nov-2003


Page: 1 2 3 4 5

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. Anniversary of one of the largest hepatitis A outbreaks in the US brings experts together
8. Futuristic system brings vision to blind
9. New fund brings children from Europe for lifesaving surgery
10. Childrens Cancer Fund brings world-class pediatric cancer specialist to Dallas
11. Womens and Childrens Hospital, Adelaide brings home national Diamond Serif Award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... Dr. Kiran ... in aesthetic surgery of the face, breast, and body. In 2018, she founded ... boutique plastic surgery and aesthetic practice in Southwest Florida. Dr. Gill and her ...
(Date:8/31/2020)... ... , ... Want to get moving, break up your routine, and make a ... to launch its fourth annual STEPtember campaign in the United States to raise funds ... they are at this moment — encouraging people to move in the ways that ...
(Date:8/31/2020)... ... ... “PTS” with Mediation & Hypnosis , At this very turbulent time in the world, ... immense stress, and right now are needing serious relief from a constant state of endless ... experiencing a great degree of emotional discomfort, be it fear or worrying about their income ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & ... was named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in ... whose ambitions deliver innovation, growth and prosperity as they build and sustain successful ...
(Date:8/28/2020)... ... , ... Ziegler, a specialty investment bank, is pleased to ... a tech-enabled behavioral health and well-being solutions provider. , Synchronous Health, a ... (AI) to increase access and quality of behavioral health services, and Adventist Health, ...
Breaking Medicine News(10 mins):
(Date:9/2/2020)... BETHESDA, Md. (PRWEB) , ... September 02, 2020 , ... ... Dr. Jonathan Lee . Dr. Lee will work at Bethesda Dermatopathology ... graduated with his B.A. from the University of California, Berkley. He went on to ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are common ... About 3% of breast cancers (about 7,500 women per year) and 10% of ovarian ... BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing Program. ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... guide, has named Cloudticity a Gold winner in the 15th Annual 2020 Network ... recogniti o ns from Network Products Guide honoring achievements of world’s ...
Breaking Medicine Technology:
Cached News: